Merck (MSD) clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
88 trials changed in the last 30 days: 1 stopped, 22 with notable changes, 65 with minor changes only.
- Minor: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Trial sites expanded: 314 → 317 locations
- Notable: MK-6916 · Pain After Bunion Removal Surgery (MK-6916-007) Recruitment opened
- Minor: Enlicitide · High Cholesterol (MK-0616-037) Trial completed
- Minor: Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) Trial sites expanded: 11 → 18 locations
- Minor: Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Breast Cancer (MK-2870-032) Trial sites expanded: 335 → 338 locations
- Minor: TroFuse-031 · Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Urothelial Cancer (MK-2870-031) Trial sites expanded: 111 → 117 locations
- Minor: INTerpath-014 · Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) Trial sites expanded: 124 → 129 locations
- Minor: Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) Trial sites expanded: 0 → 13 locations
- Notable: Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents · High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) Results posted: Nov 13, 2026
- Minor: Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments · Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) Trial completed
- Minor: Bomedemstat · Polycythemia Vera (MK-3543-025) Trial sites expanded: 5 → 8 locations
- Minor: Raludotatug Deruxtecan · Ovarian Cancer (MK-5909-003) Trial sites expanded: 39 → 42 locations
- Minor: WaveSpan-008 · MK-1045 · Non-Hodgkin Lymphoma (MK-1045-008) Trial sites expanded: 52 → 56 locations
- Minor: Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) · PH-COPD Study completion moved earlier from Oct 8, 2029 to May 1, 2027
- Notable: EXPrESSIVE-18 · Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018) Recruitment opened
- Minor: Tulisokibart (MK-7240) · Radiographic Axial Spondyloarthritis (MK-7240-013) Enrollment closed, study ongoing
- Minor: MK-8527 in Healthy Participants (MK-8527-021) Trial completed
- Minor: V540D in Healthy Adults (V540D-004) Primary and study completion pushed from Nov 30, 2026 to Jan 29, 2027
- Minor: Calderasib (MK-1084) With Targeted Therapy and Chemotherapy · Colorectal Cancer (MK-1084-012/KANDLELIT-012) Trial sites expanded: 243 → 247 locations
- Minor: KANDLELIT-013 · MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) Trial sites expanded: 120 → 125 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-16 | NCT07939399 A Study of V951A in Healthy Participants (V951A-001) | Phase 1 | Not Yet Recruiting |
| 2026-11-06 | NCT07922174 A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease… | Phase 1 | Not Yet Recruiting |
| 2026-11-05 | NCT07917754 A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large… | Phase 2/3 | Not Yet Recruiting |
| 2026-11-05 | NCT07919028 A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006) | Phase 1 | Not Yet Recruiting |
| 2026-11-02 | NCT07908524 MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate… | Phase 1/2 | Not Yet Recruiting |
| 2026-11-02 | NCT07908537 A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell… | Phase 3 | Not Yet Recruiting |
| 2026-10-28 | NCT07899905 A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension… | Phase 4 | Not Yet Recruiting |
| 2026-10-26 | NCT07895524 A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004) | Phase 2 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 34 | |
| Phase 1/2 | 35 | |
| Phase 2 | 58 | |
| Phase 2/3 | 8 | |
| Phase 3 | 100 | |
| Phase 4 | 3 |
Not charted: 2 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 49
Lung Cancer (36) · Non-Small Cell Lung Cancer (NSCLC) (25) · Kidney Cancer (16) · Bladder Cancer (13) · Non-Hodgkin Lymphoma (11) · Breast Cancer (10) · Hypertension (9) · DLBCL (8) · Leukemia (8) · Prostate Cancer (8)
Get alerts when Merck (MSD)'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.